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Abstract
We present here the isolation and characterization of Acinetobacter pittii phage vB_ApiM_fHyAci03 (fHyAci03), which 
belongs to the family Myoviridae. The fHyAci03 genome was found to be 165,975 bp in length and predicted to contain 255 
genes. While the whole genome was 92.4% identical to Acinetobacter baumannii phage KARL-1, phylogenetic analysis 
based on phage long distal tail fiber amino acid sequences assigned fHyAci03 and KARL-1 to different subclusters, reflecting 
their different host species. Together with phylogenetic analysis, genome comparisons indicated that fHyAci03 is a novel 
member of the subfamily Tevenvirinae. Host range experiments revealed that fHyAci03 could infect two clinical strains of 
Acinetobacter nosocomialis and six clinical strains of A. pittii. Thus, fHyAci03 is a novel lytic phage that infects clinical 
Acinetobacter strains and represents a potential new candidate to be used in phage therapy.
The genus Acinetobacter includes multiple nosocomial 
opportunistic pathogens. Within this genus, A. baumannii, 
A. pittii, and A. nosocomialis are the most frequently isolated 
species from hospitalized patients around the world [1]. 
Recently, these bacteria have become a public health con-
cern because of the growing tendency to develop antibiotic 
resistance [2]. Due to the continued increase in multidrug-
resistant (MDR) bacterial strains, there has been a great deal 
of recent interest in phage therapy research.
fHyAci03 was isolated from a municipal sewage sam-
ple collected in Hyvinkää, Finland, using clinical A. pittii 
strain #5565 (obtained from HUSLAB, Helsinki, Finland) 
as the host. The morphology of fHyAci03 was examined by 
transmission electron microscopy as described previously 
[3] (Supplementary Fig. 1). The dimensions of the prolate 
head were 111 ± 5.2 nm (length) and 82 ± 5.1 nm (width), 
and the tail length was 90 ± 4 nm. Dimensions were cal-
culated based on ten virions. Together with the genomic 
information, the morphological characteristics indicated that 
fHyAci03 belongs to the family Myoviridae and the sub-
family Tevenvirinae. fHyAci03 host range was tested with 
48 clinical Acinetobacter strains (Supplementary Table 1). 
Host range experiments revealed that fHyAci03 could infect 
two out of three A. nosocomialis strains, and six out of 18 A. 
pittii strains that were tested. Phage DNA was isolated using 
an Invisorb Spin Virus DNA Minikit (Stratec Biomedical). 
Next-generation sequencing was performed at the Institute 
for Molecular Medicine Finland (FIMM), using a DNA 
library that was constructed using a Nextera Sample Prep 
Kit (Illumina, San Diego, CA, USA). Paired-end sequenc-
ing was done using an Illumina MiSeq sequencer (Illumina, 
San Diego, CA, USA) with a read length of 300 nucleotides. 
Draft sequences were assembled using two pipelines in par-
allel, Geneious software, version 10.1, and the A5-miseq 
integrated pipeline [4]. The average whole-genome read 
coverage was 42.9x. Results from both pipelines were com-
pared to identify a single consensus sequence. To manually 
verify the fidelity of the assembly, the reads were mapped 
back to the contigs using Geneious (mean coverage 43.0x, 
range, 11-96x). The genome was found to be 165,975 bp in 
length, with a mean GC content of 36.8%. The genome was 
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annotated using Geneious software, RAST [5], BLASTP 
[6], ARAGORN [7], tRNAscan-SE version 2.0 [8], Res-
Finder-3.1 [9], and VirulenceFinder-2.0 [10]. fHyAci03 con-
tained 255 predicted genes, eight of which code for tRNAs 
(Supplementary table S2) and 247 for proteins (Fig. 1). No 
toxin-, virulence-factor-, antibiotic-resistance-, or lysog-
eny-related genes were found, indicating that fHyAci03 is 
strictly lytic and a potential new candidate for phage therapy. 
A BLASTn search revealed that the most closely related 
phages belonged to the subfamily Tevenvirinae (Supple-
mentary Table S3). Alignment with EMBOSS Stretcher 
showed that fHyAci03 is 92.4% identical to A. baumannii 
phage KARL-1 (MH713599.1) [11]. Prior to the sequence 
comparisons, the sequence of KARL-1 was rearranged with 
Fig. 1  Annotated genome map of fHyAci03. The predicted 247 protein-coding and eight tRNA genes are colour coded according to the key. 
Some examples of genes that are conserved within the subfamily Tevenvirinae are indicated
0.06
Escherichia_virus_T4__NC_000866@S10_G3_F3
Acinetobacter_phage_Ac42__HM032710@S3_G3_F3
Acinetobacter_phage_vB_ApiM_fHyAci03__MH460829@S8_G3_F3
Acinetobacter_phage_Acj9__HM004124@S2_G3_F3
Acinetobacter_phage_Bphi_B1251__JX403940@S6_G1_F1
Acinetobacter_phage_KARL_1__MH713599@S9_G3_F3
Enterobacteria_phage_RB49__NC_005066@S11_G4_F3
Acinetobacter_phage_phiAB6__KT339321@S7_G2_F2
Acinetobacter_phage_ZZ1__HQ698922@S5_G3_F3
Acinetobacter_virus_133__HM114315@S4_G3_F3
Acinetobacter_phage_Acj61__GU911519@S1_G3_F3
9 8 5 3
1 0 0
9 3
5 3
4 6
7 7
1 0 0
9 8
0.3
YMC/09/02/B1251_ABA_BP AFQ22133.1
133 YP_004300829.1
T4 NP_049863.1
ZZ1 YP_006489023.1
Acj61 YP_004009850.1
Ac42 YP_004009606.1
RB49 NP_891822.1
phiAB6 YP_009288671.1
KARL-1 AXY82658.1
Acj9 YP_004010381.1
vB_ApiM_fHyAci03 AXF40808.1
70 / 8 2
93 / 9 5
96 / 1 00
- / 96
61 / -
61 / -
62 / -
a
b
Fig. 2  Phylogenetic trees based on the whole-genome nucleotide 
sequences (a) and amino acid sequences of the tail fiber proteins 
(b) showing the relationships within the subfamily Tevenvirinae and 
between the families Myoviridae, Podoviridae, and Siphoviridae. 
Phages are color coded according to family/subfamily. Orange, Myo-
viridae, Tevenvirinae; blue, Siphoviridae; grey, Podoviridae 
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respect to its orientation and starting point to align maxi-
mally with the T-even phages. Genome-wide nucleotide phy-
logenetic analysis using VICTOR (Virus Classification and 
Tree Building Online Resource) [12] placed fHyAci03 in the 
same subcluster with KARL-1 (Fig. 2A). Further phyloge-
netic analysis based on phage tail fiber amino acid sequences 
using VICTOR assigned fHyAci03 and KARL-1 to differ-
ent subclusters (Fig. 2B), reflecting the difference in host 
species. Comparisons of conserved gene product content 
between fHyAci03, KARL1, and other members of the sub-
family Tevenvirinae, were performed using CoreGenes3.5 
[13] (Supplementary Table S4). Based on shared gene con-
tent (96.76 % shared homologs) and nucleotide sequence 
similarity, we suggest that fHyAci03 and KARL-1 could 
comprise a new genus within the subfamily Tevenvirinae, for 
which we propose the name “FHyAci03virus” after the first 
sequenced isolate. To conclude, fHyAci03 is a novel lytic 
phage that, with further characterization, could represent an 
interesting new candidate for phage therapy.
Nucleotide sequence accession number
The genomic sequence of fHyAci03 has been depos-
ited in the GenBank database under the accession number 
MH460829.1.
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